This article is more than 5 years old. Information may no longer be current.
ARBITER 6-HALTS
Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies
Click Here to Manage Email Alerts
Trial assessed combination of ezetimibe vs. extended-release niacin in patients with CHD for reduction in carotid intimamedia thickness.
Design: randomized, parallel
Patients: 208
Centers: 2
Countries: United States
RESULTS: Mean HDL increased by 18.4% during the 14-month study period (P<.001) and mean LDL decreased in the ezetimibe group decreased by 19.2% (P<.001). Niacin was more efficacious than ezetimibe for the change in carotid intima-media thickness over the study period (P=.003). The researchers reported that niacin therapy caused a reduction in the mean and the maximal carotid intima-media thickness at both eight and 14 months, while no significant net changes in carotid intimamedia thickness were reported in the ezetimibe group. They also reported that greater reductions in LDL in the ezetimibe group were associated with increased carotid intima-media thickness (P<.001).
Presented at AHA 2009.
Click here to read more about the ARBITER-6 HALTS trial.